Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358187 · ClinicalTrials.gov registry record · Phase 2
A Vaccine Trial for Low Grade Gliomas
A Phase 2 study of Low Grade Glioma, sponsored by James Felker.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02358187: Recruiting Phase 2 study of Low Grade Glioma, sponsored by James Felker.
NCT02358187 is a Phase 2 study of Low Grade Glioma that is actively recruiting participants, run by James Felker. The registered enrollment target is 25 participants, below the 113-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02358187, a Phase 2 study of Low Grade Glioma, is actively recruiting participants, sponsored by James Felker.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the immunogenicity, safety and preliminary clinical efficacy of the glioma associated antigen (GAA)/tetanus toxoid (TT) peptide vaccine and poly-ICLC in HLA-A2+ children with unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens. Radiation therapy counts as one biologic regimen, but patients may not have received radiation to the index lesion within 1 year of enrollment.
Primary Outcome
Participants who demonstrate radiological evidence of tumor shrinkage or stable disease without regimen-limiting toxicity (RLT) after the initial 8 vaccines will be eligible to receive additional vaccinations beginning week 24 and every 6 weeks thereafter for up to two years.
Conditions Studied
Interventions
- BIOLOGICAL Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Study Locations (1)
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT02358187 shows while recruiting
NCT02358187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 113-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Low Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC is the first listed.
NCT02358187 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02358187 about?
NCT02358187 is a clinical study titled "A Vaccine Trial for Low Grade Gliomas". The study will assess the immunogenicity, safety and preliminary clinical efficacy of the glioma associated antigen (GAA)/tetanus toxoid (TT) peptide vaccine and poly-ICLC in HLA-A2+ children with unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens. Radiatio...
What is the current status of trial NCT02358187?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-01. Estimated completion is 2028-12-31.
What conditions does trial NCT02358187 study?
This clinical trial studies the following conditions: Low Grade Glioma.
What interventions are being tested in trial NCT02358187?
The interventions under investigation include: Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC (BIOLOGICAL).
Who is sponsoring clinical trial NCT02358187?
This trial is sponsored by James Felker, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02358187 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02358187's enrollment target sits among peer trials
25 22nd of 23 higher than 2 of 23 other Low Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
RECRUITING · Phase 2
-
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia